Prostate-specific antigen as a screening test. The Netherlands experience.

At the Rotterdam site of the ERSPC approximately 9600 men between 54 and 76 years old have been randomized at the time of writing, of which 50% for screening by PSA (Hybritech Tandem E), DRE, and TRUS until March 1996. The cancer detection rate is 4.3%, and the overall biopsy-to-carcinoma rate is 5.1. By clinical staging 91% of cancers are organ-confined (T2c or less), by pathologic staging after radical prostatectomy 64% of tumors are specimen-confined. The best sole predictor of a positive biopsy is total serum PSA, followed by DRE. The specificity of PSA in the intermediate PSA range between 4 and 10 ng/mL can be improved significantly by application of the f-PSA/t-PSA ratio, PSA density and age-specific reference ranges. The f-PSA/t-PSA ratio with a cut-off value of 0.20 appears to be the most effective parameter and reduces in combination with DRE the number of biopsies in the intermediate PSA range by 38% with 12% of carcinomas undetected. This leads to an overall biopsy-to-carcinoma ratio of 4.6. The evaluation of TRUS-, DRE-, and PSA-driven biopsies will lead to a change of the screening procedure within the study.

[1]  J. Oesterling,et al.  The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. , 1995, The Journal of urology.

[2]  P. Boyle,et al.  Screening for prostate cancer--necessity or nonsense? , 1993, European journal of cancer.

[3]  J. Goméz,et al.  Serum prostate specific antigen as pre-screening test for prostate cancer. , 1992, The Journal of urology.

[4]  M. Ohori,et al.  Early detection of prostate cancer: the nature of cancers detected with current diagnostic tests. , 1994, Seminars in Oncology.

[5]  R. Vessella,et al.  Screening for prostatic carcinoma with prostate specific antigen. , 1992, The Journal of urology.

[6]  M. Benson,et al.  The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. , 1992, The Journal of urology.

[7]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[8]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[9]  Franciscus M. Bentvelsen,et al.  Modalities available for screening for prostate cancer. , 1993, European journal of cancer.

[10]  B. G. Blijenberg,et al.  The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. , 1995, Urology.

[11]  H. D. de Koning,et al.  European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam Pilot studies , 1995, Cancer.

[12]  J Drago,et al.  The American cancer society national prostate cancer detection project. Findings on the detection of early prostate cancer in 2425 men , 1991, Cancer.

[13]  M. Koch,et al.  Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen. , 1994, The Journal of urology.